House Bill No. 3717 proposes the establishment of a grant program under the newly added Chapter 491 of the Health and Safety Code, aimed at funding drug development trials for ibogaine. The goal of these trials is to secure approval from the United States Food and Drug Administration (FDA) for ibogaine as a treatment for opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions where ibogaine shows efficacy. The bill outlines the responsibilities of the Health and Human Services Commission, including the creation of a selection committee to review grant applications and the establishment of drug development trial sites equipped for cardiac intensive care.

The bill specifies that applicants for the grant must be capable of conducting the FDA trials and must provide detailed plans for various aspects of the trial, including recruitment, patient safety, and post-treatment support. Additionally, the commission is authorized to use appropriated funds and accept donations to finance the grants, with the stipulation that selected applicants must match the grant amount with their own funding. The bill also includes provisions for the delay of implementation if federal waivers are required, and it will take effect immediately upon receiving a two-thirds vote from both houses or on September 1, 2025, if that vote is not achieved.

Statutes affected:
Introduced: ()